HLA-A2 Antikörper

Produktnummer ABIN301995

Produktdetails

Target: HLA-A2

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Unkonjugiert

Applikation: Flow Cytometry (FACS), Immunoprecipitation (IP)

Spezifität: The antibody BB7.2 recognizes an extracellular epitope at the C-terminus of alpha-2 helix and a turn on one of the underlying beta strands within the human HLA-A2 histocompatibility antigen.

Kreuzreaktivität (Details): Human

Aufreinigung: Purified by protein-A affinity chromatography.

Reinheit: > 95 % (by SDS-PAGE)

Immunogen: HLA-A2 solubilised by papain

Klon: BB7-2

Isotyp: IgG2b

Anwendungsinformationen

Applikationshinweise: Flow cytometry: Recommended dilution: 1 μg/mL.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.4

Konservierungsmittel: Azide free

Handhabung: Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2-8°C. Do not freeze.

Referenzen

Liang, Zhu, Liang, Weng, Lu, Zhang, Li, Wu: "A simplified PCR-SSP method for HLA-A2 subtype in a population of Wuhan, China." in: Cellular & molecular immunology, Vol. 3, Issue 6, pp. 453-8, (2007) (PubMed).

Santin, Bellone, Ravaggi, Pecorelli, Cannon, Parham: "Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells." in: Obstetrics and gynecology, Vol. 96, Issue 3, pp. 422-30, (2000) (PubMed).

Verdegaal, Huinink, Hoogstraten, Marijnissen, Gorsira, Claas, Osanto: "Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient." in: Human immunology, Vol. 60, Issue 12, pp. 1195-206, (2000) (PubMed).

Forero, Zwirner, Fink, Fernández-Viña, Stastny: "Juvenile arthritis, HLA-A2 and binding of DEK oncogene-peptides." in: Human immunology, Vol. 59, Issue 7, pp. 443-50, (1999) (PubMed).

Lee, Loftus, Appella, Margulies, Mage: "A recombinant single-chain HLA-A2.1 molecule, with a cis active beta-2-microglobulin domain, is biologically active in peptide binding and antigen presentation." in: Human immunology, Vol. 49, Issue 1, pp. 28-37, (1997) (PubMed).

Barouch, Davenport, McMichael, Reay: "A mAb against HLA-A2 can be influenced both positively and negatively by the associated peptide." in: International immunology, Vol. 7, Issue 10, pp. 1599-605, (1996) (PubMed).

Nijman, Houbiers, Vierboom, van der Burg, Drijfhout, DAmaro, Kenemans, Melief, Kast: "Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes." in: European journal of immunology, Vol. 23, Issue 6, pp. 1215-9, (1993) (PubMed).

Peoples, Goedegebuure, Andrews, Schoof, Eberlein: "HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 151, Issue 10, pp. 5481-91, (1993) (PubMed).

Hogan, Brown: "Localization and characterization of serologic epitopes on HLA-A2." in: Human immunology, Vol. 33, Issue 3, pp. 185-92, (1992) (PubMed).

Natali, Nicotra, Bigotti, Venturo, Marcenaro, Giacomini, Russo: "Selective changes in expression of HLA class I polymorphic determinants in human solid tumors." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, Issue 17, pp. 6719-23, (1989) (PubMed).

Santos-Aguado, Barbosa, Biro, Strominger: "Molecular characterization of serologic recognition sites in the human HLA-A2 molecule." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 141, Issue 8, pp. 2811-8, (1988) (PubMed).

Scornik: "HLA-A2 epitopes recognized by alloantibodies from broadly sensitized patients." in: Human immunology, Vol. 18, Issue 4, pp. 277-85, (1987) (PubMed).

Brenner, McLean, Yang, van der Poel, Pious, Strominger: "Clonal T lymphocyte recognition of the fine structure of the HLA-A2 molecule." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 135, Issue 1, pp. 384-90, (1985) (PubMed).

Taketani, Krangel, Pious, Strominger: "Structural analysis of HLA-A2 antigen from immunoselected mutant 8.6.1: further definition of an HLA-A2-specific serological determinant." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 131, Issue 6, pp. 2935-8, (1984) (PubMed).

Krangel, Taketani, Pious, Strominger: "HLA-A2 mutants immunoselected in vitro. Definition of residues contributing to an HLA-A2-specific serological determinant." in: The Journal of experimental medicine, Vol. 157, Issue 1, pp. 324-36, (1983) (PubMed).

Pious, Krangel, Dixon, Parham, Strominger: "HLA antigen structural gene mutants selected with an allospecific monoclonal antibody." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 79, Issue 24, pp. 7832-6, (1983) (PubMed).

Parham, Brodsky: "Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28." in: Human immunology, Vol. 3, Issue 4, pp. 277-99, (1982) (PubMed).

Antigendetails

Target: HLA-A2

Substanzklasse: Influenza Protein

Hintergrund: HLA-A2 (44 kDa) is the most frequent HLA-A allele in human ethnic populations. HLA-A, together with HLA-B and HLA-C, represent human HLA class I major histocompatibility (MHC) antigens. These intrinsic membrane glycoproteins are expressed on nucleated cells and noncovalently associate with an invariant beta2 microglobulin. They carry foreign determinants important for immune recognition by cytotoxic T cells, thus important for anti-viral and anti-tumour defence.